samedan logo

home > news > detailed info

Catalent to Invest $10 Million to Expand High Potency Containment Capabilities For Micronization


SOMERSET, N.J. – December 03, 2020 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it is investing $10 million in isolator capabilities at its sites in Malvern, Pennsylvania and Dartford, U.K., to expand its micronization capabilities for highly potent drug compounds.

The investment will allow flexible jet milling operations to be carried out at both sites under containment to a working occupational exposure limit (OEL) of 0.05 micrograms per cubic meter, enabling micronization of potent and highly potent compounds, at less than 10 and less than 1 microgram per cubic meter respectively. Additionally, the capability to operate under an inert nitrogen environment offers enhanced manufacturing safety, eliminates the risk of dust explosion for compounds with low minimum ignition energy (MIE) values, and enables the processing of humidity, light and oxygen-sensitive materials. Work is underway at both facilities, with installation and validation activities likely to be completed by mid-2021.

At Dartford, the isolator will encompass a K-Tron gravimetric feeder with KT35 hopper and feed screws, suitable for 8-inch and 12-inch jet mills. The DEC Group designed system will be fully automated and allow product and waste to be collected within a safe, controlled environment. At the Malvern facility, the nine-chamber isolator will be housed within a new extension at the site, and will be one of the biggest isolators installed in the United States. The multi-chamber design, undertaken by FPS Architects & Engineers Limited, offers superior ergonomics and is optimized to significantly reduce cleaning and maintenance time.

“Catalent offers multiple tools and technologies to drug innovators to improve the characteristics and efficacy of new molecules, and micronization is an important engineering step for many materials to help improve the solubility of oral drugs and optimize inhaled therapies,” commented James Walter, Vice President Operations, Oral and Specialty Delivery at Catalent. “This investment allows us to ensure that access to this technology is not limited, as we see the development of highly potent molecules becoming more prevalent in the small molecule R&D pipeline against a number of disease targets.”

The Dartford and Malvern sites offer world-leading expertise and experience in particle size reduction capabilities including micronization, jet milling, mechanical milling, cryogenic milling and associated analytical services, and work alongside Catalent’s network of commercial-scale facilities. The company recently announced the launch of its OneXpress™ solution to integrate and accelerate a program’s transition from early-phase development to commercial-ready manufacturing by leveraging its phase-appropriate scale, technologies, extensive oral dose form network and expertise to reduce risk, complexity and cost between phases.
phone +1 888 765 8846
email 14 Schoolhouse Road, Somerset 08873 NJ , USA
Print this page
Send to a friend
News and Press Releases


-- If Approved, KTE-X19 will be an Important New Advance for this Disease with a Poor Prognosis -- -- Kite would Become the First Company with Multiple Approved CAR T Therapies in Europe --
More info >>

White Papers

Digital Transformation of the Cold Chain

Sensitech EMEA

The Life Sciences cold chain is a seamless and interconnected global network of people, equipment, data and processes that helps to ensure the safety and integrity of our medicines and vaccines. Cold chain logistics spending totaled $13 billion in 2017, an investment designed to protect some $283 billion in Life Sciences cold chain products, growing at 19% annually.1 Sensitech Inc., a part of UTC Climate, Controls & Security, a unit of United Technology Corp., has played an essential part in the Life Sciences cold chain since 1990, providing a comprehensive set of solutions for manufacturers of biologics, prescription pharmaceuticals, clinical trial materials, and over-the-counter drugs. These solutions help to ensure product quality, patient safety, and regulatory compliance while helping to prevent theft and optimizing cold chain performance.
More info >>

Industry Events

DIA Europe 2021

15-19 March 2021, VIRTUAL CONFERENCE

DIA Europe is the must-attend event for all life science professionals working in drug development, from discovery to marketed use. It encourages open collaboration by bringing together representatives from the entire spectrum of the life science landscape and facilitating crucial discussions across several topic tracks: Clinical Development, Regulatory Strategy, Pharmacovigilance, Value and Access, Health Policy, and many more.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement